These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

459 related items for PubMed ID: 23842022

  • 1. Double-blind, placebo-controlled, pilot trial of paliperidone augmentation in serotonin reuptake inhibitor-resistant obsessive-compulsive disorder.
    Storch EA, Goddard AW, Grant JE, De Nadai AS, Goodman WK, Mutch PJ, Medlock C, Odlaug B, McDougle CJ, Murphy TK.
    J Clin Psychiatry; 2013 Jun; 74(6):e527-32. PubMed ID: 23842022
    [Abstract] [Full Text] [Related]

  • 2. A Systematic Review of Evidence-based Treatment Strategies for Obsessive- compulsive Disorder Resistant to first-line Pharmacotherapy.
    Albert U, Marazziti D, Di Salvo G, Solia F, Rosso G, Maina G.
    Curr Med Chem; 2018 Jun; 25(41):5647-5661. PubMed ID: 29278206
    [Abstract] [Full Text] [Related]

  • 3. Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials.
    Dold M, Aigner M, Lanzenberger R, Kasper S.
    Int J Neuropsychopharmacol; 2013 Apr; 16(3):557-74. PubMed ID: 22932229
    [Abstract] [Full Text] [Related]

  • 4. Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial.
    Simpson HB, Foa EB, Liebowitz MR, Huppert JD, Cahill S, Maher MJ, McLean CP, Bender J, Marcus SM, Williams MT, Weaver J, Vermes D, Van Meter PE, Rodriguez CI, Powers M, Pinto A, Imms P, Hahn CG, Campeas R.
    JAMA Psychiatry; 2013 Nov; 70(11):1190-9. PubMed ID: 24026523
    [Abstract] [Full Text] [Related]

  • 5. Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial.
    Bystritsky A, Ackerman DL, Rosen RM, Vapnik T, Gorbis E, Maidment KM, Saxena S.
    J Clin Psychiatry; 2004 Apr; 65(4):565-8. PubMed ID: 15119922
    [Abstract] [Full Text] [Related]

  • 6. Ondansetron augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary, single-blind, prospective study.
    Pallanti S, Bernardi S, Antonini S, Singh N, Hollander E.
    CNS Drugs; 2009 Dec; 23(12):1047-55. PubMed ID: 19958042
    [Abstract] [Full Text] [Related]

  • 7. Randomized, Double-Blind, Placebo-Controlled Trial of N-Acetylcysteine Augmentation for Treatment-Resistant Obsessive-Compulsive Disorder.
    Costa DLC, Diniz JB, Requena G, Joaquim MA, Pittenger C, Bloch MH, Miguel EC, Shavitt RG.
    J Clin Psychiatry; 2017 Jul; 78(7):e766-e773. PubMed ID: 28617566
    [Abstract] [Full Text] [Related]

  • 8. Antipsychotic Augmentation of Serotonin Reuptake Inhibitors in Treatment-Resistant Obsessive-Compulsive Disorder: An Update Meta-Analysis of Double-Blind, Randomized, Placebo-Controlled Trials.
    Dold M, Aigner M, Lanzenberger R, Kasper S.
    Int J Neuropsychopharmacol; 2015 May 04; 18(9):. PubMed ID: 25939614
    [Abstract] [Full Text] [Related]

  • 9. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
    Bloch MH, Landeros-Weisenberger A, Kelmendi B, Coric V, Bracken MB, Leckman JF.
    Mol Psychiatry; 2006 Jul 04; 11(7):622-32. PubMed ID: 16585942
    [Abstract] [Full Text] [Related]

  • 10. Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder: a double-blind, randomized, placebo-controlled study.
    Kordon A, Wahl K, Koch N, Zurowski B, Anlauf M, Vielhaber K, Kahl KG, Broocks A, Voderholzer U, Hohagen F.
    J Clin Psychopharmacol; 2008 Oct 04; 28(5):550-4. PubMed ID: 18794652
    [Abstract] [Full Text] [Related]

  • 11. Quetiapine augmentation in obsessive-compulsive disorder resistant to serotonin reuptake inhibitors: an open-label study.
    Bogan AM, Koran LM, Chuong HW, Vapnik T, Bystritsky A.
    J Clin Psychiatry; 2005 Jan 04; 66(1):73-9. PubMed ID: 15669891
    [Abstract] [Full Text] [Related]

  • 12. A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors.
    Denys D, de Geus F, van Megen HJ, Westenberg HG.
    J Clin Psychiatry; 2004 Aug 04; 65(8):1040-8. PubMed ID: 15323587
    [Abstract] [Full Text] [Related]

  • 13. Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder.
    Berlin HA, Koran LM, Jenike MA, Shapira NA, Chaplin W, Pallanti S, Hollander E.
    J Clin Psychiatry; 2011 May 04; 72(5):716-21. PubMed ID: 20816027
    [Abstract] [Full Text] [Related]

  • 14. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder.
    McDougle CJ, Epperson CN, Pelton GH, Wasylink S, Price LH.
    Arch Gen Psychiatry; 2000 Aug 04; 57(8):794-801. PubMed ID: 10920469
    [Abstract] [Full Text] [Related]

  • 15. Double-blind study of dextroamphetamine versus caffeine augmentation for treatment-resistant obsessive-compulsive disorder.
    Koran LM, Aboujaoude E, Gamel NN.
    J Clin Psychiatry; 2009 Nov 04; 70(11):1530-5. PubMed ID: 19573497
    [Abstract] [Full Text] [Related]

  • 16. Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study.
    Li X, May RS, Tolbert LC, Jackson WT, Flournoy JM, Baxter LR.
    J Clin Psychiatry; 2005 Jun 04; 66(6):736-43. PubMed ID: 15960567
    [Abstract] [Full Text] [Related]

  • 17. Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 12-week open-label preliminary study.
    Pessina E, Albert U, Bogetto F, Maina G.
    Int Clin Psychopharmacol; 2009 Sep 04; 24(5):265-9. PubMed ID: 19629012
    [Abstract] [Full Text] [Related]

  • 18. [Efficacy of antipsychotic augmentation therapy in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomised, placebo-controlled trials].
    Dold M, Aigner M, Lanzenberger R, Kasper S.
    Fortschr Neurol Psychiatr; 2011 Aug 04; 79(8):453-66. PubMed ID: 21809258
    [Abstract] [Full Text] [Related]

  • 19. Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study.
    Hollander E, Baldini Rossi N, Sood E, Pallanti S.
    Int J Neuropsychopharmacol; 2003 Dec 04; 6(4):397-401. PubMed ID: 14604454
    [Abstract] [Full Text] [Related]

  • 20. Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762].
    Carey PD, Vythilingum B, Seedat S, Muller JE, van Ameringen M, Stein DJ.
    BMC Psychiatry; 2005 Jan 24; 5():5. PubMed ID: 15667657
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.